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A chicken bioreactor for efficient
production of functional cytokines
Lissa R. Herron1,7* , Clare Pridans1,2, Matthew L. Turnbull1,3, Nikki Smith1, Simon Lillico1, Adrian Sherman1,
Hazel J. Gilhooley1, Martin Wear4, Dominic Kurian1, Grigorios Papadakos7, Paul Digard1, David A. Hume1,2,5†,
Andrew C. Gill1,6† and Helen M. Sang1*†
Abstract
Background: The global market for protein drugs has the highest compound annual growth rate of any
pharmaceutical class but their availability, especially outside of the US market, is compromised by the high cost of
manufacture and validation compared to traditional chemical drugs. Improvements in transgenic technologies
allow valuable proteins to be produced by genetically-modified animals; several therapeutic proteins from such
animal bioreactors are already on the market after successful clinical trials and regulatory approval. Chickens have
lagged behind mammals in bioreactor development, despite a number of potential advantages, due to the historic
difficulty in producing transgenic birds, but the production of therapeutic proteins in egg white of transgenic
chickens would substantially lower costs across the entire production cycle compared to traditional cell culture-
based production systems. This could lead to more affordable treatments and wider markets, including in
developing countries and for animal health applications.
Results: Here we report the efficient generation of new transgenic chicken lines to optimize protein production in
eggs. As proof-of-concept, we describe the expression, purification and functional characterization of three
pharmaceutical proteins, the human cytokine interferon α2a and two species-specific Fc fusions of the cytokine CSF1.
Conclusion: Our work optimizes and validates a transgenic chicken system for the cost-effective production of pure,
high quality, biologically active protein for therapeutics and other applications.
Keywords: Transgenic animals, Biologics, Recombinant proteins, Cytokines, Animal biotechnology
Background
Since the development of recombinant human insulin,
protein-based therapeutics have been the fastest-growing
segment of the pharmaceutical industry. Three of the
five highest revenue drugs in oncology, Rituxan, Avastin
and Herceptin, are monoclonal antibodies [1]. The ap-
pearance of hundreds of non-antibody therapeutic pro-
teins, including enzymes, cytokines and growth factors
and blood proteins, validates predictions from 2004 [2]
that this would be an area of significant growth. Between
2011 and 2016, 62 new therapeutic protein drugs were
approved by the US FDA [3]. A further 27 were
approved between September 2016 and December 2017
[4]. Although the unique benefits of biopharmaceuticals
are clear, the costs to the health care system are becom-
ing prohibitive [5]. Prices charged have traditionally been
based upon patient benefit, but the cost of goods is also
significant, especially in the transition to generics and
biosimilars. Many biopharmaceuticals are produced
using bacterial, yeast or mammalian cell culture expres-
sion systems. Current mammalian cell-culture based sys-
tems are increasingly optimised and industrialized [6].
Each system is constrained in some measure by yield,
cost, complex purification procedures and appropriate
post-translational modification when required for bio-
logical function.
Development of genetic modification systems for live-
stock offered the possibility of harnessing natural
high-volume protein production systems (e.g. milk from
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farmed livestock and eggs from poultry) for the produc-
tion of biologics. Transgenic sheep, goats and cows were
generated that produced biopharmaceuticals in their
milk, with the aim of establishing animal bioreactors for
large scale production of high quality proteins, poten-
tially at lower capital and production costs than cell
culture systems [7, 8]. The first drug produced in a
transgenic animal, antithrombin III in goat milk, was
approved for use by the European Medicines Agency in
2006 and the FDA in 2009 [9]. However, there are limi-
tations to the use of large mammals as bioreactors. They
have few offspring, long gestation times and require a
large amount of space and feed, all of which can make
industrial scale-up difficult and expensive. It can also be
difficult to purify a recombinant protein from milk due
to the high content of lipids and other proteins [10].
Reabsorption of the protein by the animal can have
deleterious effects, particularly if the human protein is
biologically active in the host [11].
Interest in developing the laying hen as a bioreactor is
based on the high protein synthetic capacity of the hen: an
average 60 g egg contains nearly 3.5 g of protein in the egg
white [12] and each hen may lay over 300 eggs per year.
Chickens are relatively inexpensive to keep [10] and large
flocks can be built quickly from small numbers of founder
birds. In addition, chickens have closely-related glycosyla-
tion patterns to humans [12], which may result in reduced
immunogenicity of biologics from egg white, as well as
improving functionality of proteins where glycosylation is
required for activity [13–15]. We showed previously that
lentiviruses can be used for efficient production of trans-
genic chickens [16]. Transgene expression can be re-
stricted to the oviduct (and thus egg white) using
sequences from the ovalbumin gene, encoding the most
abundant egg white protein [17]. While this approach
allowed successful production of two biologically active
proteins in egg white, the expression levels achieved were
well below the > 1 g/L likely to be required as the basis of
a commercially viable system. In addition, purification of
recombinant proteins from egg white, a matrix character-
ized by high levels of other proteins including albumin
and the gel-like glycoconjugate ovomucin, remained to be
tackled [17]. Here we demonstrate the improved and
optimized production of two new proteins, including a
cytokine dimer, and robust purification protocols. Inter-
feron α2a is a legacy, off-patent biologic used to treat
certain forms of cancer and hepatitis [18–20] and was
selected as a model for biosimilar production in the
chicken system. Macrophage colony-stimulating factor
(CSF1) is a candidate therapeutic protein in many areas of
regenerative medicine [21]. Like interferon, CSF1 is a
4-helix bundle protein, structurally-related to many cyto-
kines, including insulin, somatotrophin, placental lacto-
gen, G-CSF, GM-CSF and erythropoietin (EPO) [22] that
are in widespread clinical use. Immunoglobulin Fc fusion
proteins are an emerging class of biopharmaceuticals [23,
24]. Several therapeutic 4 helix bundle proteins have been
tested as fusion proteins with the Fc region to improve
their circulating half-life and biological activity [24–28].
We recently produced a Fc fusion protein of CSF1 and
demonstrated increased in vivo efficacy in rodent and
large animal models, and potential as therapeutic in liver
regeneration [29–32]. An additional attraction of the Fc
tag in generation of therapeutic proteins in bioreactors is
that it provides a generic tag for affinity purification. Here
we demonstrate the optimal production, downstream pro-
cessing and biological activity of recombinant proteins
produced in the transgenic avian system. The chicken bio-
reactor clearly has the potential to address the cost and
availability of therapeutic proteins for both human and
veterinary medicine.
Results
Production of a high-purity, biologically active human
cytokine
Human interferon α2a is a cytokine commonly used for
treatment of hepatitis and various cancers [18–20]. The
0.5 kb coding sequence for interferon α2a was synthe-
sized and cloned into a replication-defective equine
infectious anemia virus (EIAV) lentiviral vector with a
modified form of the EREOVA promoter previously
published [17]. To increase the level of expression, we
reintroduced an additional 0.9 kb of the ovalbumin pro-
moter sequence between the estrogen response element
(ERE) and the steroid-dependent regulatory element
(SDRE) (EREOVA2; Fig. 1a, Additional file 1: Figure S1).
Transgenic birds were generated using this lentiviral
vector with our established methods [17]. A single G1
male was identified that carried an intact transgene and
a line established from this bird. The presence of
interferon α2a in egg white in hens from this line was
confirmed by western blot analysis with an antibody
against human interferon α (Fig. 1b), and concentration
measured by a commercial ELISA kit. Biological activity
before purification was confirmed by applying diluted
whole egg white to cells transfected with a reporter of
interferon-stimulated response element (ISRE) driving
luciferase expression (Fig. 1c).
A multi-step purification protocol was developed that
involves clarification of ovomucin by pH reduction and
its removal by centrifugation, and purification of the
interferon α2a by HiTrap Blue capture followed by size
exclusion chromatography (SEC) polishing; purity was
confirmed by SDS-PAGE (Fig. 1d). Recovery of inter-
feron α2a was approximately 15 mg from 100mL of egg
white, which is 60% of the original 25 mg/100 mL esti-
mate determined by ELISA, with most of the loss occur-
ring in the wash of the capture step; there is no
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observable protein loss in the ovomucin precipitation
step or polishing step (Fig. 1e). Purity of > 95% was
determined by reversed phase chromatography and
SEC-multi-angle light scattering analyzes (Additional
file 2: Figure S2).
The anti-viral properties of the purified interferon α2a
were examined using a dose-inhibition assay against an
H1N1 influenza A virus (A/Puerto Rico/8/1934 PR8) in
A549 cells pre-treated with interferon α2a. The assay
was performed as described previously [33] with
a
b
d
f
e
c
Fig. 1 (See legend on next page.)
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commercially-available interferon α2a (produced in E.
coli) as a control. The egg white interferon showed
improved activity compared to the commercial protein
(Fig. 1f), calculated to be as high as 1 × 109 U/mg, an
order of magnitude greater than the bacterially-produced
protein.
Simple purification of high quality, biologically active
porcine growth factor-Fc fusion protein
Colony stimulating factor 1 (CSF1) is required for
differentiation, proliferation and function of macro-
phages, and has shown promise as a therapeutic protein
for a variety of indications, particularly in regenerative
medicine [21, 29, 30]. Porcine CSF1 is active across
mammalian species [34], and an Fc fusion protein of
CSF1 was shown to have increased half-life and efficacy
in vivo [30]. The coding sequence for porcine CSF1
fused to an antibody Fc region (pCSF1-Fc) [30] was syn-
thesized and cloned into a pLenti6 (Invitrogen) lentiviral
vector derived from human immunodeficiency virus
(HIV), downstream of the EREOVA2 promoter and
upstream of optimized woodchuck hepatitis virus post-
transcriptional regulatory element [35] (oPRE) (Fig. 2a).
Founder (G0) cockerels were generated [17] and bred to
identify G1 transgenic birds. The presence of a single
insertion of the intact transgene was confirmed in two
hens and one cockerel by Southern blot analysis
(Additional file 3: Figure S3). The two hens had the
same insertion site (Line 1), while the cockerel had a dif-
ferent insertion (Line 2); all three were bred with stock
birds to generate G2 hens. Expression of pCSF1-Fc in
egg white was confirmed by SDS-PAGE and western
blot with an antibody against porcine Fc (Fig. 2b), and
expression was equivalent between two generations
(Additional file 4: Figure S4). To test the functionality of
pCSF1-Fc egg white, porcine CSF1 receptor was
expressed in factor-dependent Ba/F3 cells [34] as previ-
ously described [30], making them dependent on func-
tional CSF1-Fc for survival. Whole egg white from both
Line 1 hens promoted survival and proliferation at
similar concentrations to control pCSF1-Fc produced in
CHO cells [30], while wild type egg white alone was
unable to promote survival (Fig. 2c).
Egg white from pCSF1-Fc eggs was clarified of ovo-
mucin as described for interferon purification. All of
the protein came through in the supernatants (Fig.
2d). The active dimer form of pCSF1-Fc was purified
by MabSelect SuRe capture followed by size exclusion
chromatography (SEC) polishing, and purity confirmed by
SDS-PAGE (Fig. 2e). Due to the difficulty in quantifying
pCSF1-Fc in whole egg white by western blot and the lack
of an ELISA test, concentration of protein was calculated
based on the final recovery and estimates of protein loss
through the purification process based on western blots of
samples collected throughout the process (Fig. 2f). Purity
was > 97%, as determined by reversed phase chromatog-
raphy and SEC-multi-angle light scattering. The molecular
mass average across the elution profile is 95.1 kDa with
good protein mono-dispersity (Mw/Mn= 1.011) and no
significant aggregation. Co-polymer model analysis
indicated that peak mass was comprised of 85.6 kDa of
protein and 9.5 kDa of oligosaccharide (~ 10% glycosyla-
tion). (Additional file 5: Figure S5). Mass spectrom-
etry analysis confirmed the identity of pCSF1-Fc;
presence of contaminating egg white proteins was
below the limit of detection (Additional file 6: Table
S1). The Ba/F3 cell survival assay was repeated with
pCSF1-Fc purified from fresh egg white, egg white
that had been stored at -20 °C for at least 1 month,
and egg white that had been stored at -80 °C for at
least 1 month. The control pCSF1-Fc and all purified
egg pCSF1-Fc samples were able to promote cell sur-
vival at comparable levels (Fig. 2g), demonstrating
that egg white can be collected and frozen for a sig-
nificant period of time prior to purification without
loss of recovery or activity. The ability of the purified
protein to interact with the native CSF1 receptor was
confirmed using mouse bone marrow cells. Both con-
trol and egg-derived pCSF1-Fc promoted cell differen-
tiation at comparable levels (Fig. 2h).
(See figure on previous page.)
Fig. 1 Expression of biologically-active human interferon α2a by transgenic hens a Schematic representation of the interferon α2a transgene;
ovalbumin regulatory elements including the estrogen response element (ERE) and the steroid-dependent regulatory element (SDRE); lysozyme
signal peptide (LSP) for secretion; the coding sequence of human interferon α2a; EIAV long terminal repeats (LTR). b Western blot of dilutions of
transgenic egg white protein (lanes 1 and 2) and 5 μg of commercially-available interferon α2a protein (lane 3), stained with antibody for human
interferon α2a. c Activity of whole egg white assayed for activation of the interferon-stimulated response element (ISRE) by measurement of
luciferase. Egg white from transgenic hens was compared with egg white with a range of concentrations of control protein added, and wild type
egg white as a negative control. Measurements were taken in triplicate. Graph shows mean + SEM. d Interferon α2a was purified from egg white
and confirmed by reducing SDS-PAGE Instant Blue staining. e SDS-PAGE of 5 μL samples of egg white before ovomucin precipitation (lane 1),
pellet after first centrifugation (lane 2), supernatant after first centrifugation (lane 3), pellet after pH adjustment and second centrifugation (lane 4),
and supernatant after pH adjustment and second centrifugation (lane 5); and western blot of 10 μL samples from each stage of purification: Blue
Sepharose load (lane 6), Blue Sepharose flow-through (lane 7), Blue Sepharose wash (lane 8), Blue Sepharose eluate (lane 9) and final pure protein
(lane 10). f Purified interferon α2a from egg white and a purchased control protein were tested in a viral dose-inhibition assay against influenza A
virus. Measurements were taken in triplicate. Graph shows mean ± SEM
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To determine the activity of egg-derived pCSF1-Fc in
vivo, mice were treated with 1 μg/g of either control or
purified egg pCSF1-Fc, following which the livers,
spleens and blood were analyzed for weight and
histology as previously described [30]. Consistent with
previous reports, both forms of pCSF1-Fc caused an
increase in F4/80+CD11b+ cells in the blood (Fig. 3a)
and F4/80+ tissue macrophages in the liver (Fig. 3b).
a
b
d
g
h
e
f
c
Fig. 2 Expression of biologically-active porcine CSF1-Fc by transgenic hens. a Schematic representation of the pCSF1-Fc transgene, with HIV LTRs;
a modified ovalbumin promoter containing the ERE and SDRE; LSP for secretion; the coding sequence of porcine CSF1; the coding sequence of
porcine Fc; oPRE. b Egg white from wild type and transgenic hens were homogenized and diluted 1:50 in PBS (lanes 1 and 2) and separated
under reducing conditions by SDS-PAGE with CHO-cell produced pure protein (lane 3) and transferred to nitrocellulose membrane and stained
with anti-porcine Fc to confirm expression. c Activity of whole egg white was tested with a MTT cell survival assay. Whole egg white from
transgenic hens was compared with wild type egg white with four concentrations of control protein added, while wild type egg white was used
as a negative control. Measurements were taken in triplicate. Graph shows mean + SEM. d SDS-PAGE and western blot of 5 μL samples of egg
white before ovomucin precipitation (lanes 1 and 4), supernatant after first centrifugation (lanes 2 and 5), and supernatant after pH adjustment
and second centrifugation (lanes 3 and 6). e pCSF1-Fc dimer was purified from egg white as confirmed by non-reducing SDS-PAGE stained with
Instant Blue. f Western blot of 10 μL samples from each stage of purification: MabSelect SuRe load (lane 1), MabSelect SuRe flow-through (lane 2),
MabSelect SuRe wash (lane 3), MabSelect SuRe eluate (lane 4) and final pure protein (lane 5). g Activity of purified pCSF1-Fc from fresh egg
white, egg white that had been frozen at -20 °C and -80 °C for at least 1 month before purification, and CHO-cell produced pCSF1-Fc was tested
in a MTT Ba/F3-CSF1R cell-survival assay. Measurements were taken in triplicate. Graph shows mean + SEM. h Bone marrow from pigs was
cultured in CHO-cell-produced pCSF1-Fc, pCSF1-Fc or without growth factor (cells only) for 7 days. MTT was used to assess cell viability.
Measurements were taken in triplicate. Graph shows mean + SEM
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There were also significant increases in the weights of
the liver and spleen (Fig. 3c-d).
Validation of the Fc-fusion approach by production of a
potential human therapeutic cytokine
Although pCSF1-Fc is active on human cells and might
have short-term therapeutic applications in human pa-
tients and in veterinary medicine, it is likely to be im-
munogenic. Indeed, we have immunized mice with the
CSF1-Fc protein to produce monoclonal antibodies that
cross-react with human CSF1 (hCSF1; L.Waddell, DAH,
manuscript in preparation). As a prelude to testing hu-
man clinical applications, we have generated additional
chicken lines expressing a human CSF1-Fc (hCSF1-Fc)
protein using the same vector system and employing the
optimized purification protocol. The presence of a single
insertion of the intact transgene was confirmed in two
hens by Southern blot analysis (Additional file 7: Figure
S6), and both were calculated to have correct protein ex-
pression (Fig. 4a) at levels of approximately 1 mg/mL,
calculated by the same method as for pCSF1-Fc. Purifi-
cation was identical to that of pCSF1-Fc, including re-
covery efficiency (Fig. 4b). Since hCSF1 has previously
been shown to interact with pig bone marrow [34], the
bone marrow differentiation assay was repeated to test
activity of purified hCSF1-Fc, and protein from both
lines was shown to promote survival and differentiation
at an equivalent level to each other and pCSF1-Fc
control, even after vacuum drying and reconstitution
(Fig. 4c).
a
c
b
d
Fig. 3 The effect of egg purified pCSF1-Fc treatment in mice is identical to that of pCSF1-Fc from CHO cells. Mice were injected with PBS,
1 μg/g pCSF1-Fc or 1 μg/g egg purified pCSF1-Fc for 4 days prior to sacrifice on day 5. a EDTA-blood was collected via cardiac bleeds and the
percentage of F4/80+CD11b+ myeloid cells were determined by flow cytometry. Graph shows the mean + SEM. Significance is indicated by
*p = 0.0163 and **p = 0.0037 using a t-test; n = 4. b Formalin-fixed paraffin-embedded livers were stained with an antibody against F4/80. The
percentage of F4/80 staining was determined using ImageJ. Graph shows the mean + SEM. Significance is indicated by ***p = 0.0004 and ****p <
0.0001 using a test-test; n = 4. c Livers were weighed and percent body weight calculated. Graphs show the mean + SEM. Significance is indicated
by ***p = 0.0004 using a t-test. There was no significant difference between the two pCSF1-Fc populations (p = 0.2482). d Spleens were weighed
and percent body weight calculated. Graphs show the mean + SEM. Significance is indicated by ****p < 0.0001 and ***p = 0.0009 using a t-test.
There was no significant difference between the two pCSF1-Fc populations (p = 0.1122)
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These results indicate that both interferon α2a and
CSF1-Fc are efficiently synthesized as a component of
egg white, readily recoverable using common chroma-
tography methods, and biologically active in vitro and in
vivo at levels equal to control cytokines produced in dif-
ferent systems.
Discussion
Lentiviruses are efficient vectors for the generation of
transgenic chickens with stable germline transmission
and consistent, oviduct-specific expression of correctly
folded and functional protein [17]. Here we have dem-
onstrated an improved promoter design that generated
levels of expression compatible with cost-effective
scale-up. There were no negative effects on the health of
the hens despite the substantial increase in expression of
exogenous protein. The method can be applied to un-
tagged and Fc-tagged proteins, and common chromato-
graphic techniques can be applied to purify the proteins
from egg white. Initial characterization of egg-derived
proteins showed high levels of purity and activity as
good as or better than the equivalent proteins produced in
traditional cell culture or E. coli systems. Contamination
by egg proteins was below levels detectable by mass
spectrometry and in vivo testing showed no immunogenic
reaction in mice. It is likely that similarly-structured pro-
teins, including the many therapeutic Fc fusion proteins
currently under clinical evaluation [23, 24]. will be amen-
able to production in the egg white of transgenic chickens
and purification as we have described at commercially
relevant scale.
The infrastructure and upstream costs of a transgenic
chicken bioreactor production system are predicated to
be substantially lower than those for mammalian cell
culture, perhaps by as much as two orders of magnitude,
due largely to the comparably lower cost of chicken fa-
cilities and lack of requirement for GMP conditions until
egg crack. Initial analysis provided by the Centre for
Process Innovation National Biologics Manufacturing
Centre (Darlington, UK) indicates that downstream pro-
cessing costs should be equivalent to current methods,
leading to an overall lower manufacturing cost. Relative
a
c
b
Fig. 4 Expression of biologically-active human CSF1-Fc by transgenic hens. a Purity of 10 μL samples from 15mL size exclusion fractions of
hCSF1-Fc from egg white demonstrated by non-reducing SDS-PAGE stained with Instant Blue. Identity was confirmed by western blot transfer
and staining with mouse anti-human CSF1 antibody and LICOR IRDye 680RD Donkey anti-Mouse IgG (H + L) secondary antibody. b Western blot
of 10 μL samples from each stage of purification: MabSelect SuRe load (lane 1), MabSelect SuRe flow-through (lane 2), MabSelect SuRe wash (lane
3), MabSelect SuRe eluate (lane 4) and final pure protein (lane 5). c Bone marrow from pigs was cultured in purified pCSF1-Fc from egg white,
purified hCSF1-Fc from egg white, and the same protein after vacuum drying and reconstitution, or without growth factor (cells only) for 7 days.
MTT was used to assess cell viability. Measurements were taken in triplicate. Graph shows mean + SEM
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to mammalian transgenic animal bioreactors, a flock of
bioreactor chickens is faster and cheaper to produce,
and egg white is a simpler mixture of proteins with a
significantly lower lipid content than milk. In addition,
the favorable glycosylation patterns and oxidative envir-
onment of the chicken system make it appealing for
production of proteins with specific requirements for
these characteristics that are currently difficult to recap-
itulate in cell culture.
The lentivirus system was the best available at the time
of generation of these chicken lines, but since then, sig-
nificant advances have taken place in chicken primordial
germ cell culture and genome editing. Combining these
techniques means precise control over the insertion site
of the transgene and uniformity of the resulting chicken
population. It also means substantially increased effi-
ciency, reduced need for genotype screening, no bio-
safety concerns around lentiviral particles, and overall
lower upstream line generation costs, making the trans-
genic chicken bioreactor an even more appealing option.
Human interferons were amongst the first patented
biologicals. The extension of many of the therapeutic
applications of human interferon α2a (RoferonA) and
other isoforms to companion animal veterinary medicine
have been reviewed recently [36]. Interferon also has in-
creased bioavailability as a Fc fusion protein [25], and
this form would be even more readily produced in a
chicken bioreactor using the purification approach de-
scribed here. Production in chickens may bring the cost
down to levels that would support wider applications,
and extension to containment of viral diseases in valu-
able livestock. For the CSF1-Fc fusion protein, a dose of
1 mg/kg twice a week was required to produce a max-
imal elevation of blood monocyte and tissue macrophage
numbers when tested in pigs [31]. Presuming similar ef-
ficacy in humans, a single dose could be obtained from
2 to 3 eggs. One of the therapeutic applications of
CSF1-Fc already validated in mouse models is in the
treatment of bone fractures [37], an application of rele-
vance to both human and companion animal medicine.
Even if production of proteins such as CSF1-Fc in chick-
ens faces hurdles in translation to the human clinic, the
bioreactor will enable cost-effective production of the
amounts required to test clinical applications in inform-
ative large animal models.
Conclusions
We have demonstrated that a human cytokine, inter-
feron α2a, can be recovered at a level of 15 mg/100 ml
egg white (the approximate volume from 3 eggs) with
biological activity estimated as 1 × 109 IU/mg. In
addition, we have generated two transgenic lines in
which porcine and human CSF1 have been synthesized
as FC fusion proteins. Very high recovery (80–90%) from
~ 100mg/100 ml of highly pure proteins with biological
activity comparable to equivalent proteins produced in
cell culture was demonstrated. We have validated the
transgenic chicken system for the cost-effective produc-
tion of pure, high quality, biologically active proteins for
therapeutics and other applications.
Methods
Construction of transgenes
The human interferon α2a coding sequence was
codon-optimized for chicken and synthesized with a
Kozak consensus sequence, start codon and chicken
lysozyme signal peptide at the 5′ end. The synthetic
gene was ligated into a replication defective vector
derived from equine infectious anemia virus (EIAV) con-
taining a 4.4 kb modified form of the EREOVA promoter
and regulatory elements (EREOVA2) previously shown
to drive protein expression restricted to the hen oviduct
[17]. The original EREOVA promoter had 0.9 kb deleted
between the estrogen-responsive enhancer element
(ERE) and the steroid-dependent regulatory element
(SDRE) that was preserved in EREOVA2. The new pro-
moter was found to enhance protein expression in egg
white at least 10-fold compared to EREOVA. The syn-
thesized, codon-optimized gene for pCSF1-Fc (Entele-
chon, Germany) consisted of a Kozak sequence, start
codon, lysozyme signal peptide and 154 amino acid ac-
tive form of porcine CSF1 joined to the hinge-CH3 re-
gion of porcine IgG1a as previously described (13). This
transgene was cloned using designed restriction sites
AatII and NheI into a modified pLenti6/DEST Gateway
vector, with the V5 tag removed and downstream oPRE
added. This vector was derived from human immuno-
deficiency virus (HIV) and contained the EREOVA2
promoter.
Production of transgenic birds
The birds were derived from a flock of Novagen Brown
commercial egg layer strain. Lentiviral vectors were
packaged and injected into embryos from new-laid eggs
to generate G0 transgenic birds [17]. Cockerels estimated
by PCR analysis to have vector sequence present in the
germ line at frequency of > 1% were bred with wild-type
hens to generate G1 birds, which were screened by PCR
and Southern transfer analysis to confirm that the
complete gene was present as a single copy. Egg white
from G1 hens or female G2 offspring of G1 cockerels was
tested for presence of transgene-derived protein. Lines
were established from validated G1/G2 birds for each
transgene.
Protein expression analysis
Protein expression was demonstrated by SDS-PAGE and
western blot. Samples were prepared by addition of 4x
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NuPAGE LDS sample buffer, and 10x sample reducing
agent for gels that were run under reducing conditions
and heated at 70 °C for 10 min before gel electrophoresis
using Novex NuPAGE 12% Bis-Tris/MOPS gels (Life
Technologies). Proteins were transferred onto nitrocellu-
lose membranes by use of an XCell II Blot Module (Life
Technologies). Transfer was verified by Ponceau S stain-
ing and membranes were blocked overnight at 4 °C. For
westerns imaged using the LI-COR scanner, blocking
was performed with Odyssey Blocking Buffer, while for
westerns visualized using HRP, blocking was performed
with 5% (w/v) powdered milk in TBS. Interferon α2a
was detected with monoclonal anti-interferon α (Sigma,
UK, catalogue number SAB1409236) at 1:1000 dilution
and sheep anti-mouse IgG conjugated HRP (GE Health-
care NXA931-1ML) or LI-COR IRDye 680RD Donkey
anti-Rabbit IgG (H + L) at 1:20,000 dilution and imaged
with a LI-COR Odyssey Imager according to manufac-
turer’s instructions. Concentration was estimated with a
commercial ELISA kit according to manufacturer’s in-
structions (PBL Biomedical Laboratories 41,100). Due to
a lack of antibody against porcine CSF1, CSF1-Fc was
immunoblotted with anti-porcine Fc conjugated to HRP
(Bethyl Laboratories A100-104P) at a 1:10,000 dilution
in 3% (w/v) powdered milk in TBS 0.1% (v/v) Tween-20.
Interferon concentration was determined by quantitative
Western blot using LI-COR Image Studio software.
Egg white activity analysis
Whole egg white from transgenic hens’ eggs was tested
for activity prior to purification. For interferon, the
ability to stimulate interferon-stimulated response
element (ISRE)-driven transcription of luciferase was
used to determine initial whole egg white activity. The
pGL4.45[luc2P/ISRE/Hygro] vector (Promega) was
transfected in HEK293T cells seeded in white-walled
96-well plates at 1 × 104 cells/well using FuGENE HD
(Promega) according to manufacturer’s instructions. 24 h
post-transfection, the medium was replaced with
antibiotic-free medium and either egg white from trans-
genic hens or wild type egg white with control interferon
protein (Sigma) added at an estimated final concentra-
tion of 10 international units (IU), 102 IU and 104 IU,
with diluted wild type egg white used as a negative con-
trol. After a further 24 h, the One Glo Luciferase assay
kit (Promega) was used to measure luminescence ac-
cording to manufacturer’s instructions. For pCSF1-Fc, a
cell survival assay based upon the ability of viable cells
to reduce 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide (MTT) was performed as previously de-
scribed [30]. Briefly, stable Ba/F3 cells expressing
porcine CSF1 receptor were grown in complete RPMI
(10% (v/v) fetal calf serum, penicillin, streptomycin, and
GlutaMAX) and supplemented with 5% (v/v) X63 cell
supernatant from X63 Ag8–653 myeloma cells carrying
an expression vector for IL-3 (22). Cells were seeded in
96-well plates at a density of 2 × 104 cells/well in tripli-
cate and treated with serial dilutions of egg or CHO
cell-produced pCSF1-Fc instead of IL-3, with negative
controls containing complete RPMI with no X63 or
pCSF1-Fc. Plates were incubated at 37 °C, 5% (v/v) CO2
for 48 h and MTT (Sigma) at a final concentration of
0.5 mg/mL was added for a further 3-h incubation,
followed by solubilization overnight with acidified iso-
propanol. Absorbance was measured at 570 nm and re-
sults normalized to the highest dose positive control.
Protein purification and analysis
For pCSF1-Fc and hCSF1-Fc purification, egg white was
diluted 1:4 in 50mM phosphate buffer pH 3, adjusted to
pH 4, and stirred at room temperature for 10 min to pre-
cipitate ovomucin. The diluted egg white was centri-
fuged at 25,000 g for 45 min at 10 °C, the supernatant
adjusted to pH 7 and centrifuged again at 25,000 g for
45 min at 10 °C to remove any further precipitates. The
clarified egg white was diluted to a final volume of 10
times the original egg white volume and pCSF1-Fc was
bound to a 5mL HiTrap MabSelect SuRe column (GE
Healthcare) pre-equilibrated with 50mM phosphate buf-
fer, pH 7, (PB) at 5 mL/min by use of an Äkta Prime Plus
liquid chromatography system (GE Healthcare). The col-
umn was washed with 10 column volumes of PB and the
protein was eluted with 3–5 column volumes of 100 mM
citrate buffer (CB) pH 3, or until the UV peak had
returned to baseline, into tubes containing 1M Tris pH
9 at 30% of the final fraction volume. The column was
regenerated with 3 column volumes of CB and 5 column
volumes of PB, cleaned in place with 5 column volumes
of 0.5M NaOH, pH adjusted with 5 column volumes of
PB and finally cleaned with 10 column volumes of 20%
(v/v) ethanol for storage. The fractions containing eluted
protein, as determined by SDS-PAGE, were pooled and
concentrated to < 13mL in an Amicon stirred cell with
10,000 Da ultrafiltration regenerated cellulose membrane
and injected onto a Superdex 200 26/600 column (GE
Healthcare) equilibrated with PBS at 2.5 mL/min by
use of the Äkta Prime Plus. Fractions were collected
manually to ensure that only the main portion of the
correct peak was isolated. After use the column was
cleaned with 1–2 column volumes of 20% (v/v) etha-
nol and stored.
For Interferon α2a, egg white was diluted 1:4 in 20
mM phosphate buffer pH 3, adjusted to pH 4, and stirred
at room temperature for 10 min to precipitate ovomucin.
The diluted egg white was then centrifuged at 25,000 g
for 45 min at 10 °C, the supernatant adjusted to pH 7
and centrifuged again at 25,000 g for 35 min at 10 °C to
remove any further precipitates. The clarified egg white
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was diluted to a final volume of 10 times the original
egg white volume and interferon α2a was bound onto a
5 mL HiTrap Blue column (GE Healthcare) equilibrated
with 20mMPB pH 7 at 5 mL/min by use of an Äkta
Prime Plus liquid chromatography system (GE Health-
care). The column was washed with 10 column volumes
of PB and protein eluted with 20mMPB containing 1M
NaCl. The fractions containing interferon α2a, as deter-
mined by SDS-PAGE, were pooled, diluted to 10 times
the pooled volume in ddH2O to prevent salt-induced
association of interferon and ovalbumin, concentrated to
< 13mL in an Amicon stirred cell with 10,000 Da ultra-
filtration regenerated cellulose membrane and injected
onto a Superdex 200 26/600 column (GE Healthcare)
equilibrated with PBS at 2.5 mL/min by use of the Äkta
Prime Plus. After use the column was cleaned with 1–2
column volumes of 20% (v/v) ethanol and stored.
Interferon-containing fractions, as determined by
SDS-PAGE, were concentrated by Amicon filtration.
Protein concentration was determined by UV280. Iden-
tity was confirmed by SDS-PAGE and mass spectromet-
ric analyzes (Roslin Proteomics and Metabolomics
Facility) and quality was assessed by reversed phase
chromatography and SEC-multi-angle light scattering at
the Edinburgh Protein Production Facility (EPPF), Kings
Buildings, Edinburgh.
Analysis of purified Interferon α2a activity
A dose-inhibition assay was performed to determine
interferon activity compared to a commercially available
control (Sigma SRP4594). HEK 293 T cells were used to
produce influenza A/PR/8/34 (PR8) virus as described
previously (17). A549 cells were pre-treated with varying
concentrations of interferon for 24 h, then infected at
low multiplicity (MOI 0.001). After 1 h of adsorption at
37 °C, virus-containing medium was replaced with virus
growth medium (DMEM, 1 μg/mL TPCK-treated tryp-
sin, 0.14% (w/v) BSA). After 48 h, virus was harvested
and titer determined by plaque assay on MDCK cells
with an Avicel overlay (virus growth medium supple-
mented with 1.2% (v/v) Avicel) followed by toluidine
blue staining (17, 23). The virus titer was normalized to
a no-interferon control to determine dose-inhibition.
Analysis of purified pCSF1-Fc activity
In vitro activity of purified egg pCSF1-Fc was tested by
the MTT assay in Ba/F3 cells as described for whole egg
white, and in pig bone marrow cells as previously de-
scribed [30]. Briefly, pig bone marrow cells were derived
from pigs culled by captive bolt at Dryden farm as previ-
ously described [31, 38]. Cells were plated at 5 × 104
cells/well in a 96-well plate directly from frozen stocks
and grown in complete RPMI supplemented with either
CHO-derived or egg purified pCSF1-Fc at 10 ng/mL,
100 ng/mL or 1000 ng/mL. After 7 days, the culture
medium was replaced with 50 μl of 1 mg/ml MTT solu-
tion and incubated for 1 h at 37 °C. The MTT solution
was removed and tetrazolium salt solubilized with 100 μl
of solubilization agent (0.1 M HCL, 10% Triton X-100
and isopropanol) followed by incubation at 37 °C with
5% CO2 for 10min. Plates were read at 570 nm.
In vivo activity of pCSF1-Fc was tested in mice as pre-
viously described [30]. Approval was obtained from The
Roslin Institute’s and The University of Edinburgh’s Pro-
tocols and Ethics Committees. The experiments were
carried out under the authority of a UK Home Office
Project License under the regulations of the Animals
(Scientific Procedures) Act 1986. Twelve male C57BL/6
mice aged 6–8 weeks were purchased from Charles River
Laboratories (UK) and injected subcutaneously with ei-
ther PBS, 1 mg/kg pCSF1-Fc from CHO cells or 1 mg/kg
pCSF1-Fc from eggs (n = 4 per group) for 4 days and
sacrificed on day 5 by rising levels of carbon dioxide.
Liver and spleen were removed, weighed and fixed in
10% neutral buffered formalin for histological analysis.
Blood was collected by cardiac puncture and transferred
into EDTA-coated tubes, then prepared for flow cytome-
try using the Uti-Lyse kit (Dako, Ely, UK) and stained
with PE anti-mouse F4/80 (Biolegend, CA, USA, cata-
logue number 122616, 1:200) and APC anti-mouse
Mac1/CD11b (Abcam, Cambridge, UK, catalogue num-
ber ab25482, 1:2000) to identify the macrophage popula-
tion. Results were analyzed with FlowJo software.
Analysis of purified hCSF1-Fc activity
Activity of purified egg hCSF1-Fc was tested by the bone
marrow MTT assay as described for pCSF1-Fc. To test
whether the protein could withstand drying for long-term
storage and easier shipping, aliquots of protein were
brought to dryness using a Savant SPD2010 Speedvac
(Thermo) at a constant vacuum pressure of 5.1 Torr over
1.5-h without heating. The protein was reconstituted in
the same volume of ddH2O and used as described for
pCSF1-Fc in the bone marrow differentiation assay.
Statistical analysis
Analysis was performed with GraphPad Prism Version
6.04 and statistical significance was assessed using
Student’s two-tailed t-test. Resulting values were consid-
ered statistically significant at p < 0.05.
Additional files
Additional file 1: Figure S1. EREOVA2 sequence. DNA sequence of
EREOVA2 promoter. (DOCX 16 kb)
Additional file 2: Figure S2. Interferon α2A mono-dispersity, size and
purity analysis. A) Size-exclusion chromatography multi-angled light
scattering (SEC-MALS) was used to determine the molecular and mono-
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dispersity of Interferon α2A in solution. Interferon α2A eluted from a
Superdex-200 Increase 10/300 GL size exclusion column as a single peak
with slight trailing edge (≥ 96% purity; As > 2) with apparent molecular
mass of ~ 33.2 ± 2 kDa and an Rs of 2.43 ± 0.2 nm (mean ± SD, n = 3).
The molecular mass average across the elution profile is 18.7 kDa with
average mono-dispersity (Mw/Mn = 1.038) and no significant aggregation.
B) Elution profile of Interferon α2A from an RPC 5 4.6/150 ST column run.
Chromatogram shows single sharp peak, with ≥98% purity. (DOCX 486 kb)
Additional file 3: Figure S3. Confirmation of pCSF1-Fc transgene and
copy number in G1 birds by Southern transfer analysis, Southern transfer
analysis of genomic DNA from individual G1 birds. A) Samples from
6 birds positive by PCR for HIV sequence were digested with BamHI
(located at the 5′ end of the promoter) and AvrII (located at the 3′ end of
the oPRE) to generate a 6.6 kb fragment spanning most of the ovalbumin
promoter and the pCSF1-Fc coding sequence. Any smaller bands were
considered to be truncated versions of the transgene.B) Samples from
the three birds containing intact transgenes were digested with BamHI
to detect insertion events, with each event expected to show a distinct
band. (DOCX 7376 kb)
Additional file 4: Figure S4. Comparison of expression between two
generations and different individuals of pCSF1-Fc birds. 5 μL egg white
diluted 1:50 from a second generation pen (lane 1) and three third gen-
eration pens (lanes 3–5) of pCSF1-Fc, compared by non-reducing western
blot against each other and 500 ng of purified pCSF1-Fc from second
generation egg white. (DOCX 267 kb)
Additional file 5: Figure S5. pCSF1-Fc mono-dispersity, size and purity
analysis. A) Size-exclusion chromatography multi-angled light scattering
(SEC-MALS) was used to determine the molecular and mono-dispersity
of pCSF1-Fc in solution. pCSF1-Fc eluted as a single peak (≥ 97% purity;
As = 0.91) from a Superdex-200 Increase 10/300 GL size exclusion column
with apparent molecular mass of ~ 110 ± 5 kDa and an Rs of 4.03 ± 0.4 nm
(mean ± SD, n = 3). B) Elution profile of pCSF1-Fc from an RPC 5 4.6/150 ST
column run. Chromatogram shows single sharp peak, with ≥98% purity.
(DOCX 188 kb)
Additional file 6: Table S1. pCSF1-Fc purity assessed by LC-MS/MS
analysis. The purified protein sample was digested in-solution using
trypsin and analyzed on a micrOTOF-QII (Bruker) mass spectrometer.
The spectral data was searched against Uniprot porcine protein sequence
database to confirm the identity of pCSF1-Fc and against Uniprot chicken
database to check the purity from chicken egg proteins using Mascot
server. (A composite file of results from separate Mascot searches of
LC-MS/MS data.) (DOCX 332 kb)
Additional file 7: Figure S6. Confirmation of hCSF1-Fc transgene and
copy number in G1 birds by Southern transfer analysis. Southern transfer
analysis of genomic DNA from individual G1 birds. A) Samples from
7 birds positive by PCR for HIV sequence were digested with BamHI
(located at the 5′ end of the promoter) and AgeI (located at the 3′ end of
the oPRE) to generate a 6.3 kb fragment spanning most of the ovalbumin
promoter and the hCSF1-Fc coding sequence. B) Samples from the seven
birds were digested with BamHI to detect insertion events, with each
event expected to show a distinct band. (DOCX 15849 kb)
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